$29.79
0.421.44%
At close: -
Tools
Free Benzinga Pro Trial
Calendars
Trade Ideas
Short Interest
Sector
Healthcare
Region
US
AUM
9.70M
Fund Score
Franklin Genomic Advancements ETF (BATS:HELX) Quotes, Forecast and News Summary
Franklin Genomic Advancements ETF (BATS: HELX) stock price, news, charts, stock research, profile.
| Open | $29.31 |
| High | $29.79 |
| 52 Wk High | $33.98 |
| AUM | 9.70M |
| Dividend | - |
| Ex-Div Date | - |
| Volume | 4.01K |
| Market Cap | $76.49B |
| Mgmt Fee | 0.5% |
| P/E Ratio | 35.41 |
| Prev. Close | $29.37 |
| Low | $29.31 |
| 52 Wk Low | $28.30 |
| Shares Out | 300.00K |
| Yield | - |
| Div. Freq | - |
| Avg. Volume Daily | 3.71K |
| Beta | 1.08 |
| Avg. Expense Ratio | 0.5% |
| P/B Ratio | 4.34 |
Recent News
FAQ
Q
How do I buy Franklin Genomic Advancements ETF (HELX) stock?
A
You can purchase shares of Franklin Genomic Advancements ETF (BATS:HELX) through any online brokerage.
Q
Who are Franklin Genomic Advancements ETF (HELX) competitors?
A
There are no as such competitors for Franklin Genomic Advancements ETF.
Q
What is the forecast, or price target, for Franklin Genomic Advancements ETF (HELX) stock?
A
There is no analysis for Franklin Genomic Advancements ETF to provide a consensus price target.
Q
What is the current price for Franklin Genomic Advancements ETF (HELX)?
A
The stock price for Franklin Genomic Advancements ETF (BATS: HELX) is $30.27 last updated December 18, 2024 at 9:30 AM EST.
Q
Does Franklin Genomic Advancements ETF (HELX) pay a dividend?
A
There are no upcoming dividends for Franklin Genomic Advancements ETF.
Q
When is Franklin Genomic Advancements ETF (BATS:HELX) reporting earnings?
A
Franklin Genomic Advancements ETF does not have any upcoming earnings scheduled.
Q
Is Franklin Genomic Advancements ETF (HELX) going to split?
A
There is no upcoming split for Franklin Genomic Advancements ETF.
| Open | $29.31 |
| High | $29.79 |
| 52 Wk High | $33.98 |
| AUM | 9.70M |
| Dividend | - |
| Ex-Div Date | - |
| Volume | 4.01K |
| Market Cap | $76.49B |
| Mgmt Fee | 0.5% |
| P/E Ratio | 35.41 |
| Prev. Close | $29.37 |
| Low | $29.31 |
| 52 Wk Low | $28.30 |
| Shares Out | 300.00K |
| Yield | - |
| Div. Freq | - |
| Avg. Volume Daily | 3.71K |
| Beta | 1.08 |
| Avg. Expense Ratio | 0.5% |
| P/B Ratio | 4.34 |
ETF Details
| Sector | Healthcare |
| Category | Mid Performer-Mid Growth |
| Investment Style | Mid Cap Growth |
| Fund Inception | Feb 25, 2020 |
| Managers | Matthew J. Moberg |
| Definition | Most of the stocks in this Equity Fund have average financial performance and average growth potential |
Investment Policy
The Fund invests in equity securities inside and outside of the United States, including developing or emerging markets.
Top ETF Holdings
| Symbol | Name | Share % |
|---|---|---|
| MEDP | Medpace Holdings Inc | 6.31% |
| VRTX | Nvaesrtex Pharmaceutic... | 5.51% |
| REGN | Regeneron Pharmaceutic... | 5.18% |
| DHR | Danaher Corp. | 5.14% |
| TMO | Thermo Fisher Scientif... | 4.85% |
| KRYS | Krystal Biotech Inc | 4.80% |
| LLY | Eli Lilly & Co. | 4.17% |
| KR | Samsung Biologics Co L... | 3.30% |
| NTRA | Natera Inc | 3.04% |
| LN | Astrazeneca Plc, ADR | 2.60% |
Popular Channels
Tools & Features
Partners & Contributors
About Benzinga
© 2024 Benzinga | All Rights Reserved